8-K - Plus Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Plus Therapeutics, Inc. disclosed the approval of discretionary cash bonuses for its Named Executive Officers for Fiscal Year 2025 and provided an updated summary compensation table detailing their total compensation for 2025 and 2024. This information is material to investors as it details executive compensation arrangements and changes.

Key Takeaways

1The Compensation Committee approved discretionary cash bonuses for Named Executive Officers for Fiscal Year 2025 on February 9, 2026.

2Marc H. Hedrick, M.D., President and CEO, received total compensation of $5,566,732 for 2025, including a salary of $585,000, option awards of $3,531,841, restricted stock awards of $1,100,647, non-equity incentive plan compensation of $305,663, and other compensation of $43,581.

3Andrew Sims, CFO, received total compensation of $1,631,279 for 2025, including a salary of $390,000, option awards of $810,388, restricted stock awards of $264,154, non-equity incentive plan compensation of $149,175, and other compensation of $17,562.

4Norman LaFrance, M.D., the former Chief Medical Officer, stepped down from his position on June 11, 2024, and received no compensation in 2025.

5The company filed a Registration Statement on Form S-1 (File No. 333-292637) with the SEC on January 9, 2026.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

(f) of Form 8-K, set forth below is an updated “Summary Compensation Table for 2025 and 2024”, which includes the amount of discretionary cash bonuses payable t

Management Change

Executive & Director Changes

Norman LaFrance, M.D.

Former Chief Medical Officer

stepped down

Effective: 2024-06-11

stepped down from his position

Exhibits (1)

8-K